News|Podcasts|February 13, 2026

Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron

In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and a former AstraZeneca executive is charged with multiple offenses in China.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and a former AstraZeneca executive is charged with multiple offenses in China.

Eli Lilly has begun stockpiling approximately $1.5 billion worth of Orforglipron in advance of an expected FDA decision, signaling confidence in the oral GLP-1 therapy’s potential and preparing for immediate market launch if approved.

PTC Therapeutics has withdrawn its NDA for Translarna and intends to resubmit the application after addressing agency feedback. The move delays potential approval for the treatment, which targets patients with nonsense mutation Duchenne muscular dystrophy.

In international news, a former AstraZeneca executive in China has been formally charged with several offenses, highlighting ongoing scrutiny of corporate compliance and governance practices within multinational pharmaceutical operations abroad.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.